Recent Updates
Recently added Catalysts
PAHC Positive Sentiment

Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference

Wednesday, September 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Phibro Animal Health Corporation will participate in the Morgan Stanley Annual Global Healthcare Conference on September 15, 2026. The event will feature presentations from key executives, including the CEO and CFO, aimed at financial analysts and investors. This engagement underscores the company's commitment to transparency and investor relations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Phibro Animal Health is actively engaging with investors.
  • Participation in a prestigious conference highlights company visibility.
  • Leadership team will present insights to financial analysts.

Full Press Release Details

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. President & Chief Executive Officer, Daniel Bendheim; Chief Operating Officer, Larry Miller; and Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at New York Marriott Marquis in New York. The live audio presentation will be available on the

Frequently Asked Questions

When will Phibro participate in the conference?

Phibro Animal Health will participate on September 15, 2026.

Who will represent Phibro at the conference?

CEO Daniel Bendheim, COO Larry Miller, and CFO Glenn David will represent Phibro.

Where is the Morgan Stanley conference held?

The conference will be held at the New York Marriott Marquis.

What is the purpose of the conference participation?

The participation aims to engage with financial analysts and investors.

ShareAdd on Google
Tags: PAHC Viatris Investor Conferences Healthcare Phibro Animal Health Morgan Stanley healthcare conference investor relations financial analysts
Last updated: Sep 9, 2026

Biotech snapshot

Cash runway
$82M liquidity · $0M/mo burn
Low dilution risk